Natural Product (NP) Details
| General Information of the NP (ID: NP0090) | |||||
|---|---|---|---|---|---|
| Name |
Sesquiterpene lactone
|
||||
| Species Origin | Asteraceae ... | Click to Show/Hide | |||
| Asteraceae | |||||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.353
MDCK Permeability
-4.639
PAMPA
+++
HIA
-
Distribution
VDss
-0.144
PPB
68.2%
BBB
- -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
- - -
HLM Stability
- - -
Excretion
CLplasma
4.721
T1/2
2.654
Toxicity
DILI
-
Rat Oral Acute Toxicity
- -
FDAMDD
++
Respiratory
- -
Human Hepatotoxicity
+
Ototoxicity
+++
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
+
Hematotoxicity
- -
Genotoxicity
- -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Herb ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Benznidazole | Chagas disease | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Five groups of 10 female Swiss mice weighing approximately 37 g were used in this study. | |||||
| Experimental
Result(s) |
The combination of tagitinin C and Bz exerts potent antiparasitic, immunomodulatory and cardioprotective effects. | |||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | |||
| JC cells derived from ovarian cancer patient | Ovarian cancer | Homo sapiens | ||||
| JC-pl cells derived from a pleural effusion after cisplatin treatment | Ovarian cancer | Homo sapiens | ||||
| Experimental
Result(s) |
A synergistic effect of EPD and cisplatin in an ovarian drug resistant cell line as well as a synergistic effect of EPD and paclitaxel in two other ovarian cell lines. | |||||